NetworkNewsBreaks Archive - Page 2121 of 2220

MondayJun 05, 2017 12:47 pm

NetworkNewsBreaks – Pain Therapeutics, Inc. (NASDAQ: PTIE): $1.7M Grant from NIH Supports Study of Alzheimer’s Candidate

Pain Therapeutics (NASDAQ: PTIE) is trading higher on word the biopharmaceutical company has received from the National Institutes of Health (NIH) a $1.7 million research grant to study PTI-125, a drug candidate, in Alzheimer’s disease. With this grant, Pain Therapeutics can begin testing PTI-125 in human subjects. The company said it is on track to file an Investigational New Drug (IND) application in the third quarter of 2017. "We are once again grateful to the NIH for its support of our research program around PTI-125," Pain Therapeutics chairman, president and CEO Remi Barbier stated in the news release. "NIH has…

MondayJun 05, 2017 12:21 pm

NetworkNewsBreaks – Celsion Corp. (NASDAQ: CLSN) Presents “Encouraging” OVATION Study Results; Shares Surge on Heavy Volume

Shares of Celsion (NASDAQ: CLSN) are up 57.8% on volume of 15.98 million in mid-day trade after the oncology drug development company issued an update on its OVATION study, a phase Ib dose escalating clinical trial assessing the combination of GEN-1, Celsion’s DNA-based immunotherapy, with the standard of care for the treatment of newly diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. “The OVATION study has accrued patients from four major research cancer centers. We have seen highly promising clinical findings including a patient with a complete pathological response along with a very high…

MondayJun 05, 2017 12:12 pm

NetworkNewsBreaks – AntriaBio (ANTB) Files IND Application for Diabetes Candidate, Plans for Phase 1 First-in-Human Clinical Trial; Shares Lower

Shares of AntriaBio (OTCQB: ANTB) are 10% lower in morning trade after the biopharmaceutical company said it has filed an Investigational New Drug (IND) application with the FDA for AB101, the company’s once-weekly basal insulin for patients with diabetes mellitus. AntriaBio said it intends to subsequently initiate a phase 1 first-in-human clinical study to assess the safety and tolerability, pharmacokinetics and time-action profile of single ascending doses of AB101, administered to subjects with Type 1 diabetes mellitus. To view the full press release, visit: http://nnw.fm/1oHbk About AntriaBio, Inc. AntriaBio is a patient-centric biopharmaceutical growth company specializing in the development of…

MondayJun 05, 2017 10:58 am

NetworkNewsBreaks – ImageWare Systems, Inc. (IWSY) Expands Market Reach in North America with Info X Distribution Agreement

ImageWare Systems (OTCQB: IWSY), a provider of mobile and cloud-based, multi-modal biometric identity management solutions, this morning said it has entered into an agreement in which Info X Distribution will market and resell ImageWare’s GoVerifyID Enterprise Suite and SaaS solutions. "Our partnership with Info X Distribution broadens our reach to thousands of additional resellers as Info X will actively market our GoVerifyID suite of products throughout North America. We look forward to providing multi-modal biometrics to their diverse network of existing and prospective customers," ImageWare chairman and CEO Jim Miller stated in the news release. To view the full press…

FridayJun 02, 2017 12:29 pm

NetworkNewsBreak – Top 10 Mid-day Percentage Gainers on June 2, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SVON 19.23% – News: Signs definitive agreement for an acquisition transaction with Eloxx CTHR 8.43% – News: Collaborates with American Gem Society to raise Moissanite awareness YIPI 7.18% – News: Elects new member to board of directors AMMA 5.00% – News: Schedules inaugural event for August 19th at the Tampa Convention Center NK 4.92% – News: Presenting at the Jefferies 2017 Global Healthcare Conference in New York City on June 7 HPJ 4.17% –…

FridayJun 02, 2017 11:34 am

NetworkNewsBreak – Asure Software, Inc. (NASDAQ: ASUR) Engages ROTH Capital as Sole Book-Running Manager in $29.5M Public Offering

Asure Software (NASDAQ: ASUR) has successfully completed an underwritten public offering of 2,185,000 shares of its common stock at the public offering price of $13.50 per share, which includes the sale of 285,000 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. ROTH Capital Partners acted as the sole book-running manager for the offering. Gross proceeds for Asure totaled $29.5 million, which the company plans to use toward general corporate purposes and to potentially acquire or invest in complementary businesses, assets or technologies. The company has not entered into any definitive agreement with respect…

FridayJun 02, 2017 11:29 am

NetworkNewsBreak – CytoDyn Inc. (CYDY) Secures Spot at 7th Annual LD Micro Invitational

CytoDyn Inc. (OTCQB: CYDY) announced that its president and CEO, Nader Pourhassan, Ph.D., will be presenting at the 7th Annual LD Micro Invitational on Tuesday next week at noon Pacific time. Investors who wish to have a one-on-one meeting with management should contact LD Micro via the conference website at https://www.ldmicro.com/events. Those unable to attend will be able to watch a live webcast of the presentation on the Company’s website http://www.cytodyn.com under the Investors section/IR Calendar. To view the full press release, visit: http://nnw.fm/SD9iU About CytoDyn CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of…

FridayJun 02, 2017 9:39 am

NetworkNewsBreak – Player’s Network, Inc. (PNTV) Completes First Phase of Construction for Green Leaf Farms Cultivation and Production Facility

Player’s Network, Inc. (OTCQB: PNTV) this morning announced the completion of the the first phase of its 27,000-sq.-ft. facility being built in North Las Vegas for its subsidiary Green Leak Farms Holdings. mCig, Inc. (OTCQB: MCIG), the company contracted to develop and build out the facility, worked with the City of North Las Vegas and the State of Nevada to ensure Green Leaf was 100% compliant. The first phase included two vegetation and flower rooms, an extraction lab and all the needed infrastructure to support the facility. According to the press release, phase 2 and phase 3 are nearing completion…

FridayJun 02, 2017 8:00 am

NetworkNewsBreak – Exactus, Inc. (EXDI) Receives $1.60 PT from SeeThruEquity

SeeThruEquity has initiated coverage and issued a price target of $1.60 on shares of Exactus, Inc. (OTCQB: EXDI). The analyst noted that the company has an intriguing lineup of point-of-care (POC) diagnostic solutions designed to improve the markets for fibrinolytic and cancer screening. Exactus’ initial products, the FibriLyzer™ and MatriLyzer™, are POC diagnostics that can produce results from only a drop of blood, saving time and cost compared to the currently available methods. The market for POC diagnostics is set to reach to $26.3 billion by 2021, and the analyst believes the company’s diagnostics have the potential to be disruptive…

ThursdayJun 01, 2017 3:10 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Provide Update on Pivotal Phase 2b/3 Trial with PRO 140

CytoDyn (OTCQB: CYDY) today announced that its vice chairman and chief science officer, Denis R. Burger, Ph.D, will later this week provide an update on the pivotal Phase 2b/3 trial with PRO 140 as a combination therapy in treatment-experienced HIV patients at the ASM Microbe 2017 Conference. An abstract of the pivotal Phase 2b/3 study is expected to be available online after the conference concludes. To date, PRO 140 has been evaluated in more than 300 HIV patients in various studies. It has shown potent antiviral activity with HIV patients infected with the R5 strain of HIV, which accounts for…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks